

**PROLLENIUM EXPANDS PRODUCT DEVELOPMENT ACTIVITIES IN
CANADA; SIGNS LICENSE AND DEVELOPMENT RESEARCH PACT WITH
THE UNIVERSITY OF TORONTO**

For Immediate Release

For More Information Contact:

Ario Khoshbin

1.905.508.1469

E-Mail: ario@prollemium.com

Toronto, On. Feb 12, 2009; IN its bid to maintain a leadership role in the burgeoning global aesthetics marketplace, Aurora based Prollemium Medical Technologies, Inc, . (www.prollemium.com) has inked a licensing and product development deal with the Leslie Dan Faculty of Pharmacy at the University of Toronto in Canada. The Agreement, which signals Prollemium Medical's commitment to increasing its product development activities in Canada, focuses on the commercialization of a new dermal filler based on the University of Toronto's invention of an injectable polymer for localized delivery, and the development of a totally unique dermal filler using new biomaterials or combinations thereof.

Prollemium Medical is in the business of designing, developing, manufacturing and marketing for the global marketplace, proprietary and uniquely formulated specialty pharma products keyed to the anti-aging and facial aesthetic (image enhancement) marketplace. The Company's REVANESSE® line of hyaluronic acid based dermal fillers are administered by trained dermatologists, plastic surgeons and other clinical specialists for the purposes of fostering and enhancing skin repair and skin augmentation. Since its introduction in 2006, REVANESSE® has become well recognized as a long lasting dermal filler that will erase fine lines and wrinkles, smooth deep folds and give lips a natural, fuller look.

Explains Dr. Christine Allen, Associate Professor, Department of Pharmacy, University of Toronto, “Our collaborative research with Prolenium will lead to the development of an innovative new generation of dermal filler products with superior performance capabilities”.

Adds Khasha Ighanian, Senior Vice-President, Marketing “This agreement with the University of Toronto is very gratifying for both our company in Canada, as well as our European affiliate, AuraGenix N.V. It forges a partnership of unusual scope and dimension with the University of Toronto’s formidable pharmaceutical research facilities which have long been recognized for some of the most dramatic and important breakthroughs in pharma science.” Mr. Ighanian continues, “As for the highly innovative development work we are doing with the University with regards to using new biomaterials for our second generation dermal filler products, I’d say that we now about 6-8 months away from initial human testing and about 12-18 months away from initiating the registration process. That said, once this new dermal filler product line is ready for commercialization, Prolenium will have one the most novel and unique dermal fillers on the global marketplace. This will give us a tremendous leverage over competitors in every market we serve in North America, Europe and Asia.”